

ASX RELEASE

27 September 2021

Amplia to Present at Proactive Investors Lifesciences Webinar

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) will be providing a presentation at the Proactive Investors Lifesciences Webinar at 12:00 pm AEST on Tuesday 28 September 2021. The webinar will include results from the Company’s successful Phase 1 clinical trial of AMP945 and its plans for a Phase 2 clinical trial in first-line pancreatic cancer that is scheduled to commence in early 2022.

To join the webinar, please register at: <https://event.webinarjam.com/register/91/gqy97hzy>

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).